Profound TG reduction achieved by APOC3 siRNA therapy is associated with an apolipoprotein pattern resembling APOC3 heterozygous deficiency, as well as a coordinated anti-inflammatory response, suggesting that deep APOC3 silencing remodels lipoprotein composition and may contribute to inflammation resolution by modulating apoptosis-related pathways.
Abstract
RBD5044, a GalNAc-conjugated small interfering RNA (siRNA) targeting APOC3, demonstrated robust lipid-lowering efficacy in a Phase I clinical trial. It achieved a 70% reduction in plasma triglyceride (TG) levels, with over 50% reduction maintained at six months. Elevated apoC-III concentrations have previously been associated with dysregulated lipid metabolism and pro-inflammatory states.
This biomarker substudy aimed to characterize changes in circulating apolipoproteins and systemic inflammatory biomarkers following the administration of a single dose of RBD5044 in healthy participants.
In the single-ascending-dose phase of the randomised, double-blind, placebo-controlled Phase I trial, six cohorts received subcutaneous RBD5044 in doses ranging from 5 to 150 mg. Biomarker analyses were performed at baseline and on day 31 post dosing, the established timepoint for maximum pharmacodynamic effect. Serum apolipoproteins were quantified using a proteomic platform based on mass spectrometry (ApoEdge™, ProteomEdge), and inflammatory biomarkers were evaluated using the Olink Target 96 Inflammation panel. The analysis focused on participants achieving >50% TG reduction post-treatment. Multivariate modelling (OPLS-DA) was applied to identify biomarker signatures associated with treatment response.
RBD5044 induced dose-dependent decrease in apoC-I, apoC-II, apoC-III and apoC-IV. OPLS-DA revealed a distinct biomarker profile among subjects with pronounced TG lowering. Notably, broad downregulation of systemic inflammatory mediators, including cytokines and chemokines, was observed, together with upregulation of apoptosis-related proteins involved in resolving inflammation.
Profound TG reduction achieved by APOC3 siRNA therapy is associated with an apolipoprotein pattern resembling APOC3 heterozygous deficiency, as well as a coordinated anti-inflammatory response. These findings suggest that deep APOC3 silencing remodels lipoprotein composition and may contribute to inflammation resolution by modulating apoptosis-related pathways.Figure 1Figure 2
Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up.
S. Tsimikas, E. Morgan, J. Sharma et al.· European Heart Journal· 0 citations
In healthy volunteers and subjects with mild dyslipidemia, single subcutaneous doses of EDP167 demonstrated a favorable safety and tolerability profile and a dose-dependent reduction in ANGPTL3 and substantial reductions in TG, LDL-C, non-HDL-C, ApoB and remnant-C were observed.
J. Wang, B. Jiang, Shi-Long Zhong et al.· European Heart Journal· 0 citations
Hypertriglyceridaemia is characterised by accumulation of triglyceride-rich lipoproteins (TRLs) contributing to residual atherosclerotic cardiovascular risk. Olezarsen is a GalNAc-conjugated antisense oligonucleotide targeting hepatic ApoC-III mRNA, thereby lowering ApoC-III and accelerating TRL clearance. We per...
A. C. Fernandez, S. M. Topete, M. Mejia et al.· European Heart Journal· 0 citations
Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters, and this findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowerin...
Andrea Sorrentino· Bleeding Thrombosis and Vasc...· 0 citations
Apolipoprotein C3 (APOC3) is involved in the metabolism of triglyceride (TG) and is a novel target for the treatment of hypertriglyceridemia. HRS-7249 is a small interfering RNA designed to disrupt and inhibit the expression of APOC3 and consequently lower TG level.
This phase 1 study aimed to assess the s...
L. Zhu, T. Luo, X. Ren et al.· European Heart Journal· 0 citations
GLP-1 receptor agonists confer pleiotropic vascular protection via mechanisms other than glycemic and body weight control. Comprehensive proteomic evaluations of its immunothrombosis modulatory and vascular effects remained limited.
To investigate the immunothrombosis modulatory effects of GLP-1 receptor a...
Y. Chan, S. Rakesh, T. Chan et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.